Glucagon News and Research

RSS

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

GLP-1 users say the drugs quiet food noise but do not replace lifestyle change

A qualitative study of 30 US adults found that GLP-1 receptor agonists often reduced “food noise,” psychological hunger, and appetite, helping patients feel more able to make deliberate lifestyle changes.

8 Jun 2026

GLP-1 therapies linked to fewer complications in adults with both obesity and autoimmune disease

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

7 Jun 2026

Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies

EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.

4 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026

GLP-1 treatments may reduce knee replacement surgery rates

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open access journal Regional Anesthesia & Pain Medicine.

2 Jun 2026

GLP-1 therapy linked to slower biological aging processes

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease.

2 Jun 2026

GLP-1 medications linked to lower breast cancer risk in women

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

2 Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

1 Jun 2026

Justicia carnea extract alleviates oxidative stress in pancreatitis

Chronic pancreatitis is an inflammatory disease and is difficult to manage despite advancements in medical science.

1 Jun 2026

How common spices may improve gut, brain, and metabolic health

The health effects of spices are explored, revealing their potential to influence blood sugar, inflammation, and brain function through various mechanisms.

28 May 2026

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Why blood pressure rises faster in women after midlife

This review examines how sex-specific blood pressure trajectories are shaped by genetics, hormones, metabolic risk factors, lifestyle exposures, environmental stressors, and medical treatments. It highlights that women generally have lower blood pressure earlier in life but may experience steeper increases with aging, especially around and after menopause, with exogenous stressors appearing to have a greater impact in women than in men.

27 May 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

Indian adapted Mediterranean diet targets inflammation in heart disease trial

The paper describes a single-center randomized controlled trial testing whether an Indian Adapted Mediterranean Diet can reduce dietary inflammation in adults with stable coronary artery disease or moderate-to-high cardiovascular risk. The protocol will assess changes in the Dietary Inflammatory Index, inflammatory biomarkers, cardiometabolic risk factors, body measurements, and metabolic hormones over six months.

25 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026